# A Study of ERAS-601 in People With Chordoma

> **NCT06957327** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Chordoma

## Interventions

- **DRUG:** ERAS-601

## Key facts

- **NCT ID:** NCT06957327
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957327, "A Study of ERAS-601 in People With Chordoma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06957327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*